Averin Capital Acquisition Corp appoints Akiko Moni Miyashita to board

Averin Capital Acquisition Corp.

Akiko Moni Miyashita, age 70, appointed to Board effective May 28, 2026.
She is founder of Beacon Hill Strategy Group; previously served on Halozyme Therapeutics board.
Over 25 years experience in strategy, finance, corporate development; former EVP and Chief Strategy Officer at Valo Health.
Signed joinder to letter agreement waiving certain redemption rights and voting in favor of initial business combination.
Entered into standard director indemnity agreement with the Company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Akiko Moni Miyashita

Director

ACAA · Averin Capital Acquisition Corp.

Effective: 2026-05-28
Filed: May 29, 2026, 4:30 PM ET

On May 28, 2026, the board of directors (the “ Board ”) of Averin Capital Acquisition Corp. (the “ Company ”) appointed Akiko Moni Miyashita as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Akiko Moni Miyashita was appointed as Director at Averin Capital Acquisition Corp..

Action: appointed
Role: Director

Exact text from the filing

On May 28, 2026, the board of directors (the “ Board ”) of Averin Capital Acquisition Corp. (the “ Company ”) appointed Akiko Moni Miyashita as a member of the Board, effective immediately.

View on SEC.gov

Averin Capital Acquisition Corp. filing history →

Source: SEC EDGAR

accession 0001213900-26-062863

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.